NCT02114268View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

342

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Respiratory Syncytial Virus Infections
Interventions
DRUG

MEDI8897 Intravenous

Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.

DRUG

Placebo

Participants received placebo on Day 1.

DRUG

MEDI8897 Intravenous

Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.

DRUG

MEDI8897 Intravenous

Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.

DRUG

MEDI8897 Intramuscular

Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.

DRUG

MEDI8897 Intramuscular

Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.

Trial Locations (1)

Unknown

Research Site, Overland Park

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY